References
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424 - 30; http://dx.doi.org/10.1038/nature04869; PMID: 16724053
- Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007; 35:1461 - 7; http://dx.doi.org/10.1042/BST0351461; PMID: 18031246
- Damiano V, Caputo R, Bianco R, D’Armiento FP, Leonardi A, De Placido S, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12:577 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-05-1943; PMID: 16428503
- Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 2007; 104:12468 - 73; http://dx.doi.org/10.1073/pnas.0705226104; PMID: 17636117
- Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, et al. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. Br J Cancer 2013; 108:1616 - 23; http://dx.doi.org/10.1038/bjc.2013.153; PMID: 23571736
- Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS, et al. Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res 2011; 30:84; http://dx.doi.org/10.1186/1756-9966-30-84; PMID: 21929816
- Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012; 2012:281261; http://dx.doi.org/10.1155/2012/281261; PMID: 21876693
- Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449 - 56; http://dx.doi.org/10.1016/S0140-6736(08)61039-9; PMID: 18653228
- Kuzel T, Dutcher J, Ebbinghaus S, Gordon M, Grubbs S, Khan K, et al. A phase 2 multicenter, randomized, open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma. Proc 8th Intern Kidney Cancer Symposium2009, Sep 25–26 2009, Chicago, IL, USA.
- Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7:E58 - 65; http://dx.doi.org/10.3816/CGC.2009.n.025; PMID: 19815483